CD11c/CD18: novel ligands and a role in delayed-type hypersensitivity - PubMed (original) (raw)
. 2007 Jun;81(6):1395-403.
doi: 10.1189/jlb.1106680. Epub 2007 Mar 27.
Affiliations
- PMID: 17389580
- DOI: 10.1189/jlb.1106680
CD11c/CD18: novel ligands and a role in delayed-type hypersensitivity
Chanchal Sadhu et al. J Leukoc Biol. 2007 Jun.
Abstract
CD11c, a member of the leukointegrin family, is expressed prominently on tissue macrophages and dendritic cells and binds to complement fragment (iC3b), provisional matrix molecules (fibrinogen), and the Ig superfamily cell adhesion molecule, ICAM-1. CD11c has been proposed to function in phagocytosis, cell migration, and cytokine production by monocytes/macrophages as well as induction of T cell proliferation by Langerhans cells. Using assays to quantify CD11c-mediated cell adhesion, we demonstrate that CD11c recognizes ICAM-2 and VCAM-1. The CD11c-binding site on VCAM-1 appears to be different from that used by the integrin alpha4. CD11c and alpha4beta1 contributed to monocyte capture and transmigration on inflamed human aortic endothelial cells. We discovered that the anti-mouse CD11c mAb N418 blocks CD11c binding to iC3b, ICAM-1, and VCAM-1. Treatment of mice with N418 reduced SRBC-induced delayed-type hypersensitivity significantly. CD11c appeared to contribute predominantly to the sensitization phase and somewhat less to the response to SRBC challenge. This suggests a novel role for CD11c during leukocyte recruitment, antigen uptake, and the survival of APC.
Similar articles
- LFA-1 and VLA-4 involved in human high proliferative potential-endothelial progenitor cells homing to ischemic tissue.
Duan H, Cheng L, Sun X, Wu Y, Hu L, Wang J, Zhao H, Lu G. Duan H, et al. Thromb Haemost. 2006 Dec;96(6):807-15. Thromb Haemost. 2006. PMID: 17139377 - The leukocyte integrin alpha D beta 2 binds VCAM-1: evidence for a binding interface between I domain and VCAM-1.
Van der Vieren M, Crowe DT, Hoekstra D, Vazeux R, Hoffman PA, Grayson MH, Bochner BS, Gallatin WM, Staunton DE. Van der Vieren M, et al. J Immunol. 1999 Aug 15;163(4):1984-90. J Immunol. 1999. PMID: 10438935 - Adhesion molecules mediating recruitment of monocytes to inflamed tissue.
Patarroyo M. Patarroyo M. Immunobiology. 1994 Oct;191(4-5):474-7. doi: 10.1016/S0171-2985(11)80453-5. Immunobiology. 1994. PMID: 7713561 Review. - VCAM-1/alpha 4-integrin adhesion pathway: therapeutic target for allergic inflammatory disorders.
Foster CA. Foster CA. J Allergy Clin Immunol. 1996 Dec;98(6 Pt 2):S270-7. doi: 10.1016/s0091-6749(96)70075-1. J Allergy Clin Immunol. 1996. PMID: 8977536 Review.
Cited by
- VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis.
Wolf MM, Madden MZ, Arner EN, Bader JE, Ye X, Vlach L, Tigue ML, Landis MD, Jonker PB, Hatem Z, Steiner KK, Gaines DK, Reinfeld BI, Hathaway ES, Xin F, Tantawy MN, Haake SM, Jonasch E, Muir A, Weiss VL, Beckermann KE, Rathmell WK, Rathmell JC. Wolf MM, et al. J Clin Invest. 2024 Apr 15;134(8):e173934. doi: 10.1172/JCI173934. J Clin Invest. 2024. PMID: 38618956 Free PMC article. - Integrins in Health and Disease-Suitable Targets for Treatment?
Klaus T, Hieber C, Bros M, Grabbe S. Klaus T, et al. Cells. 2024 Jan 23;13(3):212. doi: 10.3390/cells13030212. Cells. 2024. PMID: 38334604 Free PMC article. Review. - CD11c+ B cells in relapsing-remitting multiple sclerosis and effects of anti-CD20 therapy.
El Mahdaoui S, Hansen MM, von Essen MR, Hvalkof VH, Holm Hansen R, Mahler MR, Jennum P, Sellebjerg F, Romme Christensen J. El Mahdaoui S, et al. Ann Clin Transl Neurol. 2024 Apr;11(4):926-937. doi: 10.1002/acn3.52009. Epub 2024 Feb 8. Ann Clin Transl Neurol. 2024. PMID: 38332555 Free PMC article. - Controlling Antigen Fate in Therapeutic Cancer Vaccines by Targeting Dendritic Cell Receptors.
Wijfjes Z, van Dalen FJ, Le Gall CM, Verdoes M. Wijfjes Z, et al. Mol Pharm. 2023 Oct 2;20(10):4826-4847. doi: 10.1021/acs.molpharmaceut.3c00330. Epub 2023 Sep 18. Mol Pharm. 2023. PMID: 37721387 Free PMC article. Review. - Targeting integrin pathways: mechanisms and advances in therapy.
Pang X, He X, Qiu Z, Zhang H, Xie R, Liu Z, Gu Y, Zhao N, Xiang Q, Cui Y. Pang X, et al. Signal Transduct Target Ther. 2023 Jan 2;8(1):1. doi: 10.1038/s41392-022-01259-6. Signal Transduct Target Ther. 2023. PMID: 36588107 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous